PubRank

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Clinical Trial ID NCT00600210

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00600210

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Global cancer statistics, 2002. CA Cancer J Clin 2005 119.22
2 Angiogenesis in cancer and other diseases. Nature 2000 28.28
3 Cancer statistics, 2005. CA Cancer J Clin 2005 25.65
4 Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003 11.95
5 Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999 9.16
6 Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999 5.89
7 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005 3.83
8 Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992 3.77
9 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995 2.96
10 Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993 2.85
11 Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995 2.44
12 Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 2005 2.24
13 Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995 2.02
14 Use of CT simulation for treatment of cervical cancer to assess the adequacy of lymph node coverage of conventional pelvic fields based on bony landmarks. Int J Radiat Oncol Biol Phys 2005 1.69
15 Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994 1.63
16 Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995 1.55
17 P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 2003 1.54
18 Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996 1.50
19 Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999 1.49
20 Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998 1.36
21 Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999 1.23
22 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003 1.16
23 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996 1.15
24 Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000 1.07
25 Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001 1.02
26 Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999 1.00
27 Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006 0.97
28 Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 1999 0.97
29 Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995 0.97
30 VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005 0.96
31 Different angiogenic pathways in human cervical cancers. Gynecol Oncol 1998 0.96
32 Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996 0.95
33 Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997 0.95
34 Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000 0.95
35 The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997 0.94
36 Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 1999 0.94
37 Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999 0.94
38 Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004 0.93
39 Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002 0.92
40 Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett 2002 0.91
41 The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000 0.89
42 Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 1996 0.88
43 Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 1998 0.88
44 Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers. Gynecol Oncol 2005 0.84
45 Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003 0.82
46 Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001 0.80
47 Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer. Oncol Rep 2000 0.77
48 Tumor angiogenic activity of gynecologic tumor cell lines on the chorioallantoic membrane. Gynecol Oncol 1988 0.77
Next 100